T-cell engagers

News

Swiss biotech Veraxa vaults to Nasdaq listing with SPAC deal

Cancer drug developer Veraxa Biotech has reached a deal to merge with a SPAC in a deal that will give it a Nasdaq listing and a $1.6bn-plus valuation.

News

Ouro makes debut with $120m for autoimmune disease TCEs

Ouro launches today with $120m in funding and a plan to develop bispecific antibody-based T cell engagers for autoimmune diseases.

Oncology

ASCO 2024 - Matteo Levisetti

ASCO 2024 marked the 10th anniversary of checkpoint inhibitors, which powerfully changed the nature of cancer immunotherapy.

Swiss biotech Veraxa vaults to Nasdaq listing with SPAC deal

Ouro makes debut with $120m for autoimmune disease TCEs

ASCO 2024 - Matteo Levisetti

Fears US drug pricing deal will weigh heavy on the NHS

How to meet your physicians where they are online

Editor's Picks